Testosterone Therapy in Men with Heart Disease

A research team from the Intermountain Medical Center Heart Institute recently studied 755 male patients, ranging from 58-78 years, who all had severe coronary artery disease, the most common type of heart disease. In this study, participants were separated into three different groups, receiving varied doses of testosterone, administered intravenously or by gel. By the end of the first year, 64 patients who did not receive any testosterone supplements had serious adverse cardiovascular events, with only 12 who were taking medium doses of testosterone and 9 who were taking high doses did. At the end of 3 years, 125 patients who had not received testosterone therapy suffered severe cardiovascular events, whereas only 38 medium-dose and 22 high-patients did. Patients who were given testosterone as part of their follow-up treatment did much better than patients who had not been given testosterone supplementation. The non-testosterone-therapy patients were 80 percent more likely to suffer an adverse event. "Although this study indicates that hypo-androgenic men with coronary artery disease might actually be protected by testosterone replacement, this is an observational study that doesn't provide enough evidence to justify changing treatment recommendations," said the co-director of cardiovascular research at the Intermountain Medical Center Heart Institute. "It does, however, substantiate the need for a randomized clinical trial that can confirm or refute the results of this study." This new study confirms the findings of a previous study from the Intermountain Medical Center Heart Institute, that found that testosterone therapy did not increase the risk of experiencing a heart attack or stroke for men with low testosterone levels with no prior history of heart disease. Contact us for more information.